全膝关节置换术中局部浸润镇痛添加非甾体抗炎药增加肾功能不全患者急性肾损伤风险:倾向匹配回顾性队列研究
该回顾性队列研究纳入单中心2020年1月至2024年4月择期初次全膝关节置换术患者,比较局部浸润镇痛中是否添加酮咯酸(30 mg)对急性肾损伤发生率的影响。在慢性肾病组(n=114)中,含酮咯酸者急性肾损伤发生率较高(12.7% vs 2.0%,P=0.041);无慢性肾病组(n=870)无差异(2.0% vs 1.9%,P=1.0)。总体急性肾损伤发生率为2.6%。作者认为慢性肾病患者应高度谨慎使用酮咯酸,肾功能正常者可在局部浸润镇痛中安全使用。
要点
- 慢性肾病患者局部浸润镇痛含酮咯酸时急性肾损伤发生率12.7% vs 2.0%(P=0.041)。
- 无慢性肾病患者含与不含酮咯酸急性肾损伤发生率2.0% vs 1.9%(P=1.0),无显著差异。
- 总体急性肾损伤发生率为2.6%;作者认为慢性肾病患者应高度谨慎使用酮咯酸。
核心结论
- 在慢性肾病患者中,全膝关节置换术局部浸润镇痛添加酮咯酸与更高的急性肾损伤风险相关,骨科医生应高度谨慎。
- 肾功能正常患者可在局部浸润镇痛中安全给予酮咯酸,不增加急性肾损伤风险。
- 需要进一步研究其他非甾体抗炎药用于局部浸润镇痛时的急性肾损伤发生率。
研究设计与样本
- 回顾性队列研究,纳入单家三级机构2020年1月至2024年4月择期初次全膝关节置换术患者。
- 术中给予局部浸润镇痛,含或不含非甾体抗炎药酮咯酸30 mg;有无慢性肾病患者分别分析。
- 对慢性肾病组进行倾向匹配,校正年龄、性别、体重指数、美国麻醉医师协会评分及糖尿病/高血压。
- 采用t检验或卡方检验判断统计学显著性。
主要发现
- 慢性肾病组(n=114)中,局部浸润镇痛含酮咯酸者急性肾损伤发生率12.7% vs 不含者2.0%(P=0.041)。
- 无慢性肾病组(n=870)中,含酮咯酸者急性肾损伤发生率2.0% vs 不含者1.9%(P=1.0)。
- 总体急性肾损伤发生率为2.6%。
临床怎么用
- 作者认为,慢性肾病患者在全膝关节置换术局部浸润镇痛中使用酮咯酸应高度谨慎,因其与更高的急性肾损伤风险相关。
- 作者认为,肾功能正常患者可在局部浸润镇痛中安全给予酮咯酸,不增加急性肾损伤风险。
- 作者提出,需进一步研究其他非甾体抗炎药用于局部浸润镇痛时的急性肾损伤发生率。
局限性
- 需要进一步研究其他非甾体抗炎药用于局部浸润镇痛时的急性肾损伤发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Local infiltration analgesia (LIA) is a crucial component of pain management during total knee arthroplasty (TKA), Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly included in the drug cocktail. The use of NSAIDs are associated with adverse renal, gastrointestinal, and cardiovascular effects. This study aimed to investigate whether the addition of an NSAID in LIA affects the incidence of acute kidney injury (AKI) in TKA patients, especially those who have pre-existing renal impairment. The secondary aim was to determine overall AKI incidence. METHODS: A retrospective cohort study was conducted on elective, primary TKA patients in a single tertiary institution between January 2020 and April 2024. Patients were administered LIA intraoperatively, with or without an NSAID (30 mg of ketorolac). Patients who did or did not have chronic kidney disease (CKD) were analyzed separately. Propensity matching was performed on the CKD group, correcting for age, sex, body mass index, American Society of Anesthesiologists score, and presence of diabetes mellitus/hypertension. The outcome of interest was the incidence of AKI. We used t-tests or Chi-square tests to determine the statistical significance of the results. RESULTS: In patients who had CKD (n = 114), the presence of ketorolac in LIA was associated with a higher AKI incidence (12.7 versus 2.0%, P = 0.041). In patients who did not have CKD (n = 870), the presence of ketorolac in LIA was not associated with a higher AKI incidence (2.0 versus 1.9%, P = 1.0). Overall AKI incidence was 2.6%. CONCLUSIONS: In patients who have CKD, orthopaedic surgeons should be highly cautious of administering ketorolac in LIA during TKA, as it is associated with a higher risk of AKI. Patients who have normal renal function can be safely given ketorolac in LIA without an elevated risk of AKI. Further studies are needed to examine AKI incidence when other NSAIDs are used in LIA.
引用
- Chee BRK, Quah ESH, Zhao CXS, et al. The Addition of a Nonsteroidal Anti-inflammatory Drug in Local Infiltration Analgesia During Total Knee Arthroplasty Increases the Risk of Acute Kidney Injury in Patients Who Have Renal Impairment: A Propensity-Matched Retrospective Cohort Study. J Arthroplasty. 2024. PMID: 39447933. doi:10.1016/j.arth.2024.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。